Skip to content

The Neuralert Stroke Monitor Pilot Trial

The Neuralert Stroke Monitor Pilot Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06368193
Enrollment
50
Registered
2024-04-16
Start date
2024-12-12
Completion date
2027-05-01
Last updated
2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke, Surgery

Brief summary

This trial aims to demonstrate that the Neuralert Monitoring System will detect strokes before they would be identified by current standard of care. Each patient will be monitored for up to five days, depending on device connectivity or battery duration. Each monitoring session will consist of wearing a Neuralert device on each arm. For this pilot trial, we are interested in learning about Wi-Fi connectivity, successful data transmission, integration into clinical workflow, usability and tolerability.

Interventions

Device to identify upper extremity asymmetry in patients who are high risk for stroke.

Sponsors

Neuralert Technologies LLC
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Male or female age ≥ 22 years 2. Admitted or planned admission to one of the participating hospitals and followed by the Cardiothoracic (CT) Surgery or Vascular Surgery services 3. Considered at high risk for stroke while in the hospital based on: Ø Interventions or procedures that are high-risk for stroke performed during the hospitalization, which may include: * Intracardiac surgical or endovascular procedures, including valve replacement * Ascending aorta or aortic arch surgical or endovascular repair * Open surgical or endovascular carotid revascularization Ø Other cardiac procedures along with a high-risk medical history: * Age ≥ 80 years · Prior stroke/TIA * Hypercoagulable state (i.e., prior clotting events attributed to active malignancy or a diagnosed thrombophilia) requiring lifelong anticoagulation * Severely reduced left ventricular cardiac ejection fraction (i.e., \<30%) or anterior left ventricular wall akinesis * Atrial fibrillation 4. Admitted with a stroke or TIA attributed to large artery occlusion or severe stenosis that has not been revascularized.

Exclusion criteria

(all must be no) 1. Any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study 2. Baseline preoperative asymmetric upper extremity weakness as assessed by the Investigator, defined as a differential in the NIHSS upper extremity motor score between the two arms of \>0 3. Above the wrist amputation 4. Unwilling to provide informed consent or no legally authorized representative willing to provide consent if the patient is unable 5. Currently imprisoned

Design outcomes

Primary

MeasureTime frameDescription
Time to Nursing ResponseUp to 5 days post patient surgeryThe time from the nurse receiving an alert to the time they respond after assessing the patient.
Time to Generate AlertUp to 5 days post patient surgeryThe time to successful generation of an alert to staff when asymmetry or low battery is detected.

Secondary

MeasureTime frameDescription
Number of Strokes IdentifiedUp to 5 days post patient surgeryThe number of strokes identified by the Neuralert device and the number of strokes identified by usual care. If a stroke is identified at the next clinical evaluation after an alarm occurs, it will be considered to have been detected by the Neuralert device.
Device TolerabilityUp to 5 days post patient surgeryThe tolerability and impact on clinical workflow and patient feedback on tolerability after study completion.

Countries

United States

Contacts

CONTACTBrett Cucchiara, MD
cucchiar@pennmedicine.upenn.edu(215) 662-6738

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026